Saturday 31 October 2026 Export ABBV’s income statement to Excel — free account

AbbVie Inc.

ABBV Healthcare Drug Manufacturers General

AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

294.90 4.11 +1.41%

Follow ABBV

Alert me

Market cap: $513.9B
P/E: 83.3×
Fwd P/E: 38.6×
Dividend yield: 2.35%
F-score: 8/9
Altman Z: 2.31
Beneish M: −2.86
Dividend safety: 44/100

Overview Business Profile Earnings & Analysis Segments Filings

AbbVie Inc. (ABBV) revenue by segment, product and region

	Q4 FY2015	Q3 FY2015	Q2 FY2015	Q1 FY2015	Q4 FY2014	Q3 FY2014	Q2 FY2014	Q1 FY2014	Q4 FY2013	Q3 FY2013	Q2 FY2013	Q1 FY2013
H U M I R A	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Hcv	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
All other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Lupron	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Synthroid	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Imbruvica	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Synagis	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Kaletra	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Andro Gel	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Creon	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Sevoflurane	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Duodopa	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Dyslipidemia Products	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Revenue	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

AbbVie Inc. (ABBV) revenue by segment, product and region

Stockrow Weekly